| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
|
Cortiula, Francesco
|
|
|
184 |
C |
p. 172-178
|
artikel
|
| 2 |
Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
|
Roulleaux Dugage, Matthieu
|
|
|
184 |
C |
p. 179-196
|
artikel
|
| 3 |
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
|
Ducreux, Michel
|
|
|
184 |
C |
p. 137-150
|
artikel
|
| 4 |
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)
|
Wang, Jiayu
|
|
|
184 |
C |
p. 73-82
|
artikel
|
| 5 |
Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]
|
Conforti, Fabio
|
|
|
184 |
C |
p. 197-198
|
artikel
|
| 6 |
Corrigendum to ‘Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry’ [Eur J Cancer 180 (2023) 71–84]
|
Ecker, Jonas
|
|
|
184 |
C |
p. 200-201
|
artikel
|
| 7 |
Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]
|
Decaudin, Didier
|
|
|
184 |
C |
p. 199
|
artikel
|
| 8 |
eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma
|
Moya-Plana, Antoine
|
|
|
184 |
C |
p. 120-123
|
artikel
|
| 9 |
Faecal haemoglobin concentration predicts all-cause mortality
|
Deding, Ulrik
|
|
|
184 |
C |
p. 21-29
|
artikel
|
| 10 |
Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors
|
Xin, Zhaodan
|
|
|
184 |
C |
p. 124-136
|
artikel
|
| 11 |
Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
|
Lai-Kwon, Julia
|
|
|
184 |
C |
p. 83-105
|
artikel
|
| 12 |
Letter Re: Metabolic switch in cancer – Survival of the fittest
|
Hsu, Chen-Xiong
|
|
|
184 |
C |
p. 60-61
|
artikel
|
| 13 |
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)
|
Nakamura, Atsushi
|
|
|
184 |
C |
p. 62-72
|
artikel
|
| 14 |
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
|
Robson, Mark E.
|
|
|
184 |
C |
p. 39-47
|
artikel
|
| 15 |
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Holmes, Frankie A.
|
|
|
184 |
C |
p. 48-59
|
artikel
|
| 16 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
|
Fasching, Peter A.
|
|
|
184 |
C |
p. 1-9
|
artikel
|
| 17 |
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials
|
Rossini, Daniele
|
|
|
184 |
C |
p. 106-116
|
artikel
|
| 18 |
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
|
Wada, Akihisa
|
|
|
184 |
C |
p. 30-38
|
artikel
|
| 19 |
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial
|
Kawakami, Hisato
|
|
|
184 |
C |
p. 10-20
|
artikel
|
| 20 |
Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis
|
Trinkner, Paul
|
|
|
184 |
C |
p. 151-171
|
artikel
|
| 21 |
The response rate by tumour type for tissue-agnostic approved drugs
|
Haslam, Alyson
|
|
|
184 |
C |
p. 117-119
|
artikel
|
Tijdschrift beschrijving